Get the Stockscreener App
0.1544
23.52%
0.0294
After Hours:
.14
-0.0144
-9.33%
Tnf Pharmaceuticals Inc stock is traded at $0.1544, with a volume of 289.53M.
It is up +23.52% in the last 24 hours and up +18.77% over the past month.
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.
See More
Previous Close:
$0.125
Open:
$0.155
24h Volume:
289.53M
Relative Volume:
12.60
Market Cap:
$2.19M
Revenue:
-
Net Income/Loss:
$-23.66M
P/E Ratio:
-0.0112
EPS:
-13.84
Net Cash Flow:
$-10.14M
1W Performance:
+44.30%
1M Performance:
+18.77%
6M Performance:
-85.36%
1Y Performance:
-92.00%
1-Day Range:
$0.1279
$0.1739
1-Week Range:
$0.1075
$0.1739
52-Week Range:
$0.0849
$2.16
Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile
Name
Tnf Pharmaceuticals Inc
Sector
Industry
Phone
856-848-8698
Address
1185 AVENUE OF THE AMERICAS, NEW YORK
Compare TNFA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNFA
Tnf Pharmaceuticals Inc
|
0.1544 | 1.77M | 0 | -23.66M | -10.14M | -13.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Tnf Pharmaceuticals Inc Stock (TNFA) Latest News
Detecting price anomalies in TNF Pharmaceuticals Inc. with AIEquity Performance Forecast Based on AI Models - Newser
Signal strength of TNF Pharmaceuticals Inc. stock in tech scannersWeekly High Conviction Trade Setup Analysis - Newser
Will TNF Pharmaceuticals Inc. see short term momentumPrice Action Summary and Entry Strategy Guide - Newser
How TNF Pharmaceuticals Inc. stock performs during market volatilityStock Trading Session Highlights and Summary - Newser
TNF Pharmaceuticals Stock Soars 6.4% on Short Squeeze Speculation - AInvest
What institutional investors are buying TNF Pharmaceuticals Inc. stockRetirement Planning Insights For 2025 - jammulinksnews.com
What makes TNF Pharmaceuticals Inc. stock price move sharplyAI Volatility Forecast and Risk Monitor - Newser
Published on: 2025-07-28 17:03:00 - metal.it
Using RSI to spot recovery in TNF Pharmaceuticals Inc.Trade Flow Monitor with Volume Tracker - Newser
How many analysts rate TNF Pharmaceuticals Inc. as a “Buy”Maximize returns with smart investment plans - jammulinksnews.com
What are TNF Pharmaceuticals Inc. company’s key revenue driversUnlock exclusive stock market insights - jammulinksnews.com
Is it the right time to buy TNF Pharmaceuticals Inc. stockHigh-performance stocks for savvy investors - jammulinksnews.com
Should I hold or sell TNF Pharmaceuticals Inc. stock in 2025Free Investment Case Studies - jammulinksnews.com
What is TNF Pharmaceuticals Inc. company’s growth strategyStay ahead with daily expert stock picks - jammulinksnews.com
How does TNF Pharmaceuticals Inc. compare to its industry peersCapitalize on emerging trends for profits - jammulinksnews.com
TNF Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayHigh Accuracy Alerts - Newser
Is TNF Pharmaceuticals Inc. a good long term investmentOutstanding capital appreciation - PrintWeekIndia
What drives TNF Pharmaceuticals Inc. stock priceAccelerated earnings growth - PrintWeekIndia
TNF Pharmaceuticals Plunges 9.09% Amid Patent Concerns - AInvest
Best Stocks in India for Inflation Protection Stock Trend Prediction ToolsTriple-digit profit margins - PrintWeekIndia
What analysts say about TNF Pharmaceuticals Inc. stockHigh-profit capital plays - PrintWeekIndia
Company Inc. stock priceHigh-return market picks - Autocar Professional
TNF Pharmaceuticals Inc. Stock Analysis and ForecastLightning-fast growth - Autocar Professional
What drives KTOS stock priceFree Predictions - Autocar Professional
Global Indemnity Group LLC Preferred Security Stock Analysis and ForecastHigh-profit trading signals - Autocar Professional
Bullish Pattern Emerging on Max India Limited (MAXIND)Record-breaking gains - Autocar Professional
Virtu Financial Inc. Stock Analysis and ForecastMassive portfolio appreciation - jammulinksnews.com
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket - Benzinga
TNF Pharmaceuticals Plunges 11.63% Amid AI-Driven Volatility - AInvest
High Growth Stocks in India s Emerging Markets Buy Low Sell HighFree Investment Community - jammulinksnews.com
Leverage AI to personalize sales outreach and increase customer conversionChart Breakout Alert - Newser
How to Capitalize on India’s Economic Growth Through Stocks Professional Stock RecommendationsPhenomenal returns - Autocar Professional
A Tale of Resilience: SES AI Corporation Amid Stock Market Turbulence - investchronicle.com
TNF Pharmaceuticals: A 35% Intraday Surge Amid Biotech Turmoil – What’s Brewing? - AInvest
Pre-market Movers: PMN, GCTK, TELO, SRPT... - RTTNews
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket - Benzinga
TNF Pharmaceuticals Stock Soars 37.5% on Bullish Sentiment - AInvest
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why - newsable.asianetnews.com
Tnf Pharmaceuticals Inc Stock (TNFA) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):